[1] Shamsudeen I, Hegele RA.Safety and efficacy of therapies for chylomicronemia[J].Expert Rev Clin Pharmacol,2022,15(4):395-405. [2] Surendran RP, Visser ME, Heemelaar S,et al.Mutations in LPL,APOC2, APOA5,GPIHBP1 andIMF1 in patients with severe hypertriglyceridaemia[J]. J Intern Med,2012,272(2):185-196. [3] Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia[J]. J Clin Lipidol,2018,12(4):920-927. [4] Lima JG, Helena C Nobrega L, Moura Bandeira FT,et al. A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases[J].Atherosclerosis,2021,322:31-38. [5] Cao C, Liu Y, Liu L,et al. Identification of a compound heterozygous lmf1 variants in a patient with severe hypertriglyceridemia - Case report and literature review[J].J Atheroscler Thromb,2024,31(7):1106-1111. [6] Jiang J, Wang Y, Ling Y, et al.A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis[J].Lipids Health Dis,2016,15:12. [7] Perera SD, Wang J, McIntyre AD,et al. Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants[J].J Clin Lipidol,2023,17(5):659-665. [8] Kuthiroly S, Yesodharan D, Radhakrishnan N,et al. Lipoprotein lipase deficiency[J].Indian J Pediatr,2021,88(2):147-153. [9] Falko JM. Familialchylomicronemia syndrome: A clinical guide for endocrinologists[J].Endocr Pract,2018,24(8):756-763. [10] Scherer J, Singh VP, Pitchumoni CS,et al. Issues in hypertriglyceridemic pancreatitis:An update[J].J Clin Gastroenterol, 2014,48(3):195-203. [11] Wang Q, Wang G, Qiu Z, et al.Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: A systematic review and meta-analysis of observational studies[J]. J Clin Gastroenterol,2017,51(7):586-593. [12] 何文华,祝荫,朱勇,等. 高TG血症与其他病因所致急性胰腺炎的病情严重程度及预后比较[J].中华医学杂志,2016,96(32):2569-2572. [13] Pascual I, Sanahuja A, García N,et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients[J].Pancreatology,2019,19(5):623-629. [14] Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia[J].Curr Atheroscler Rep, 2023,25(10):701-709. [15] Williams L, Rhodes KS, Karmally W, et al.Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span[J]. J Clin Lipidol,2018,12(4):908-919 . [16] Williams L, Wilson DP.Editorial commentary: Dietary management of familial chylomicronemia syndrome[J].J Clin Lipidol,2016,10(3):462-465. [17] Gallo A, Béliard S, D'Erasmo L, et al. Familial chylomicronemia syndrome(FCS): Recent data on diagnosis and treatment[J].Curr Atheroscler Rep,2020,22(11):63. [18] Xia Y, Zheng W, Du T,et al. Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency[J].J Clin Lipidol,2023,17(6):808-817. [19] Aljouda L, Nagy L, Schulze A. Long-term treatment of lipoprotein lipase deficiency with medium-chain triglyceride-enriched diet: A case series[J].Nutrients,2023,15(16):3535. [20] Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study[J]. J Clin Lipidol,2018,12(4):898-907. |